Thus, the question raised is whether muscle Nrk2 downregulation results in a depletion of NAD+ levels in cancer cachexia or whether Nrk2 downregulation is related to its other functions such as modulation of muscle mass. The gene discussed is NMRK2; the disease is cancer.